Fairfield Financial Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,878
Closed -$187K 143
2024
Q4
$187K Sell
1,878
-5,548
-75% -$572K 0.07% 67
2024
Q3
$843K Buy
7,426
+1,231
+20% +$146K 0.29% 43
2024
Q2
$767K Buy
+6,195
New +$798K 0.23% 44
2023
Q4
$418K Buy
3,832
+2,407
+169% +$250K 0.16% 53
2023
Q3
$147K Buy
1,425
+779
+121% +$84K 0.06% 77
2023
Q2
$74.5K Buy
646
+4
+0.6% +$454 0.03% 113
2023
Q1
$68K Buy
642
+99
+18% +$10.7K 0.03% 118
2022
Q4
$60.3K Buy
543
+187
+53% +$19.1K 0.03% 115
2022
Q3
$30.6K Buy
356
+3
+0.8% +$268 0.01% 150
2022
Q2
$32.2K Buy
353
+3
+0.9% +$266 0.01% 140
2022
Q1
$28.7K Buy
+350
New +$27.6K 0.01% 157

Other funds holding MRK

Fairfield Financial Advisors's MRK Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Merck (MRK) in Q1 2025, closing a stake of 1,878 shares — an estimated $187K sold.

Fairfield Financial Advisors first reported a position in MRK in Q1 2022 and held it in 11 quarters. The position peaked at $843K in Q3 2024. 3,447 funds tracked by Wall St. Rank hold MRK as of Q1 2025.

  • Fairfield Financial Advisors reported no remaining Merck position as of Q1 2025 after selling out during the quarter.
  • Fairfield Financial Advisors sold 1,878 Merck shares in Q1 2025, an estimated $187K.
  • Fairfield Financial Advisors first reported a position in Merck in Q1 2022 and held it in 11 quarters.
  • Fairfield Financial Advisors's Merck position peaked at $843K in Q3 2024.
  • 3,447 funds tracked by Wall St. Rank held Merck as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.